Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluation of Innate and Adaptive Immune Responses to the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccine: Insights from an Ancillary Study of the EBL2001 Phase 2 Trial

  • By

  • Christine Lacabaratz

  • Mélany Durand

  • Aurélie Wiedemann

  • Emile Foucat

  • Mathieu Surénaud

  • Corinne Krief

  • Lydia Guillaumat

  • Cynthia Robinson

  • Kerstin Luhn

  • Viki Bockstal

  • Rodolphe Thiébaut

  • Laura Richert

  • Yves Lévy

  • July 16, 2024

Share

  • 1

    The EBL2001 phase 2 trial evaluated the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine, leading to its EU market authorization in 2020.

  • 2

    The study analyzed immune responses, revealing increased inflammatory markers and durable EBOV-specific T-cell proliferation post-vaccination.

  • 3

    Correlations were found between EBOV-specific CD8+ T-cell proliferation, cytotoxic phenotype, and low levels of the inflammatory marker IL-8.

  • 4

    The vaccine regimen demonstrated safety and robust immune responses, persisting for at least one year after vaccination.

  • 5

    This study provides insights into the roles of CD8+ T cells and inflammation in the efficacy of the Ad26.ZEBOV, MVA-BN-Filo vaccine.

Original Source(s)

Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial

  • by Christine Lacabaratz, Mélany Durand, Aurélie Wiedemann, Emile Foucat, Mathieu Surénaud, Corinne Krief, Lydia Guillaumat, Cynthia Robinson, Kerstin Luhn, Viki Bockstal, Rodolphe Thiébaut, Laura Richert, Yves Lévy

  • July 16, 2024

Related Content

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

Evaluation of Access to Licensed Vaccines for High-Risk Infectious Diseases: A Comprehensive Review and Interpretive Analysis of Ebola Virus Disease

Bundibugyo Ebola without vaccines or therapeutics: why public health fundamentals matter more than border closures